Nonalcoholic steatohepatitis (NASH)


Fatty liver disease is a common but ‘silent’ disease, which means that most people are completely unaware that they have it. As there are no symptoms to alert you to the problem, the fat in the liver keeps building up, and can result in a condition known as non-alcoholic steatohepatitis (NASH).2
Although the exact cause is unknown, we are aware of certain risk factors that make it more likely for some people to develop  NASH:3


Do you have NASH?

You may want to consider participating in the ESSENCE study evaluating an investigational drug for its ability to treat NASH.

ION224-CS2 study

Diagnosed with NASH?

You may qualify for the ION224-CS2 study.

What is the ION224-CS2 study?

The ION224-CS2 study is a clinical research study testing whether an investigational* study drug can safely improve liver health in people with NASH. There are currently no approved drugs for NASH. The ION224-CS2 study is researching a way to meet this currently unmet need.


Diagnosed with NASH?

You or your loved one could be eligible to participate in a global clinical trial of an investigational NASH treatment.

It has been estimated that NASH, an advanced form of fatty liver disease, impacts up to 6% of the world’s population, or nearly 500 million people. Yet, there are no approved NASH medications in most countries around the world, including the U.S.


Join the search for a way to manage NASH

NASH (nonalcoholic steatohepatitis) occurs when too much fat builds up in the liver and causes liver damage. NASH doesn’t have many symptoms, which makes it hard to diagnose. It can lead to other complications, like liver failure and heart attack. A clinical study by 89Bio is researching a treatment that may help those living with NASH.

NN9500-4656 study

Do you have NASH?

Consider participating in the NN9500-4656 study evaluating three investigational drugs for their ability to treat Non-Alcoholic Steatohepatitis (NASH).

Join NN9500-4656 for up to 19 months of expert care where your health is in focus.